Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM5SCF)

• Drug Name: ONC201 Drug Info
• Synonyms: Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid

Indication

Disease Entry	ICD 11	Status	REF
Endometrial cancer	2C76	Phase 2	[1]
Glioma	2A00.0	Phase 2	[1]
Multiple myeloma	2A83	Phase 2	[1]
Neuroendocrine cancer	2B72.1	Phase 2	[1]
Recurring respiratory infection	CA07-CA45	Phase 2	[1]
leukaemia	2A60-2B33	Phase 1/2	[1]
Lymphoma	2A80-2A86	Phase 1/2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 73777259
  CAS Number: CAS 1616632-77-9
  TTD Drug ID: DMM5SCF

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[3]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[4]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[4]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[5]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[6]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[7]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[8]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[9]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[9]
Pfizer 10	DM6ER9L	Female sexual arousal dysfunction	HA01.1	Phase 1	[10]

Drug(s) Targeting Dopamine receptor (DR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Neupro	DMHEAB1	Restless legs syndrome	7A80	Phase 4	[11]
EVK-001	DMG4UJ6	Diabetic gastroparesis	DA41.00	Phase 3	[12]
ABBV-951	DMMWO7V	Parkinson disease	8A00.0	Phase 3	[13]
L-piperazino-3-phenyl-indane derivative 1	DM1STAD	N. A.	N. A.	Patented	[14]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[15]
Haloperidol	DM96SE0	Delirium		Approved	[16]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[17]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[18]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[19]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[20]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[21]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[22]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[23]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[1]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Antagonist	[1]
Dopamine receptor (DR)	TTWFZ1N	NOUNIPROTAC	Antagonist	[2]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [6] Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
• [9] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [10] Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
• [11] Rotigotine Transdermal Patch: A Review in Parkinson's Disease. CNS Drugs. 2019 Jul;33(7):707-718.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Ann Neurol. 2021 Jul;90(1):52-61.
• [14] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [15] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [16] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [17] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [18] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [19] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [21] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [22] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [23] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [24] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.